Characterization of CDNF-Secreting ARPE-19 Cell Clones for Encapsulated Cell Therapy

Cerebral dopamine neurotrophic factor (CDNF) shows beneficial effects in rodent models of Parkinson’s and Alzheimer’s disease. The brain is a challenging target for protein therapy due to its exclusive blood–brain barrier. Hence, the therapeutic protein should be delivered directly to the brain parenchyma. Implantation of encapsulated mammalian cells that constantly secrete CDNF is a potential approach for targeted and long-term protein delivery to the brain. In this study, we generated several CDNF-secreting cell clones derived from human retinal pigment epithelial cell line ARPE-19, and studied CDNF secretion from the clones maintained as monolayers and in polymeric microcapsules. The secretion of wild type (wt) CDNF transgene was low and the majority of the produced protein remained intracellular, locating mainly to the endoplasmic reticulum (ER). The secretion of wtCDNF decreased to even lower levels when the clones were in a non-dividing state, as in the microcapsules. Both codon optimization and deletion of the putative ER-retrieval signal (four last amino acids: KTEL) improved CDNF secretion. More importantly, the secretion of KTEL-deleted CDNF remained constant in the non-dividing clones. Thus, cells expressing KTEL-deleted CDNF, in contrast to wtCDNF, can be considered for cell encapsulation applications if the KTEL-deleted CDNF is proven to be biologically active in vivo.

[1]  P. Zamorano,et al.  CDNF induces the adaptive unfolded protein response and attenuates endoplasmic reticulum stress-induced cell death. , 2018, Biochimica et biophysica acta. Molecular cell research.

[2]  M. Saarma,et al.  Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential , 2017, Neurobiology of Disease.

[3]  Eric Westman,et al.  Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device , 2016, Alzheimer's Research & Therapy.

[4]  M. Knip,et al.  Increased circulating concentrations of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 diabetes , 2016, Scientific Reports.

[5]  F. Amaya,et al.  A Comparative Analysis of the Molecular Features of MANF and CDNF , 2016, PloS one.

[6]  P. Permi,et al.  Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity , 2015, Cell Death and Disease.

[7]  H. Tanila,et al.  Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice , 2015, Behavioural Brain Research.

[8]  D. Söll,et al.  Codon Bias as a Means to Fine-Tune Gene Expression. , 2015, Molecular cell.

[9]  J. Uney,et al.  Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Gorka Orive,et al.  Encapsulated cell therapy for neurodegenerative diseases: from promise to product. , 2014, Advanced drug delivery reviews.

[11]  Xiaomin Wang,et al.  AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model , 2013, Experimental Neurology.

[12]  M. Saarma,et al.  Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease , 2013, Brain and behavior.

[13]  Yun Wang,et al.  Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Secretion and Cell Surface Binding Are Modulated by KDEL Receptors* , 2012, The Journal of Biological Chemistry.

[14]  Weng Tao,et al.  Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. , 2012, Investigative ophthalmology & visual science.

[15]  B. Hoffer,et al.  CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in Mice , 2012, Cell transplantation.

[16]  Chengqun Huang,et al.  Mesencephalic Astrocyte-derived Neurotrophic Factor Protects the Heart from Ischemic Damage and Is Selectively Secreted upon Sarco/endoplasmic Reticulum Calcium Depletion* , 2012, The Journal of Biological Chemistry.

[17]  Ove Almkvist,et al.  Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[18]  M. Yliperttula,et al.  A laboratory-scale device for the straightforward production of uniform, small sized cell microcapsules with long-term cell viability. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[19]  M. Saarma,et al.  Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease , 2011, Experimental Neurology.

[20]  J. Sørensen,et al.  Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  M. Yliperttula,et al.  Alginate-based microencapsulation of retinal pigment epithelial cell line for cell therapy. , 2008, Biomaterials.

[22]  O. Lindvall,et al.  Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? , 2008, Experimental Neurology.

[23]  L. Ruddock,et al.  A molecular specificity code for the three mammalian KDEL receptors , 2007, The Journal of cell biology.

[24]  M. Saarma,et al.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo , 2007, Nature.

[25]  Weng Tao,et al.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  David I. Smith,et al.  MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. , 2003, Journal of molecular neuroscience : MN.

[27]  Weng Tao,et al.  Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. , 2002, Investigative ophthalmology & visual science.

[28]  L. Hjelmeland,et al.  ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. , 1996, Experimental eye research.